Yang Li

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

Journal of gynecologic oncology

Translational cancer research

Cancer management and research

Zhejiang University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Zhejiang University Sep 01 2007 - Jun 30 2012

China

PHD

Publications

Jian Zou, Yang Li, Tingting Chen, Changkun Zhu
An E7-retinoblastoma protein pathway mechanism may account for the higher carcinogenic ability of HPV16 over HPV58 in cervical cancer. Translational cancer research 13 (4) (2024)
Jian Zou, Yang Li, Tingting Chen, Changkun Zhu
An E7-retinoblastoma protein pathway mechanism may account for the higher carcinogenic ability of HPV16 over HPV58 in cervical cancer. Translational cancer research 13 (4) (2024)
Yang Li, Changkun Zhu, Hongyu Xie, Yaxia Chen, Wei-Guo Lv, Xing Xie, Xinyu Wang
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of gynecologic oncology 34 (2) (2023)
Yang Li, Changkun Zhu, Hongyu Xie, Yaxia Chen, Wei-Guo Lv, Xing Xie, Xinyu Wang
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of gynecologic oncology 34 (2) (2023)
Yang Li, Changkun Zhu, Hongyu Xie, Yaxia Chen, Wei-Guo Lv, Xing Xie, Xinyu Wang
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of gynecologic oncology 34 (2) (2023)
Yang Li, Changkun Zhu, Hongyu Xie, Yaxia Chen, Wei-Guo Lv, Xing Xie, Xinyu Wang
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of gynecologic oncology 34 (2) (2023)
Yang Li, Changkun Zhu, Hongyu Xie, Yaxia Chen, Wei-Guo Lv, Xing Xie, Xinyu Wang
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). Journal of gynecologic oncology (2023)
Shizhou Yang, Tingting Chen, Lu Huang, Shanshan Xu, Zhu Cao, Songfa Zhang, Junfen Xu, Yang Li, Yongfang Yue, Weiguo Lu, Xiaodong Cheng, Xing Xie
High-Risk Human Papillomavirus E7 Maintains Stemness Via APH1B In Cervical Cancer Stem-Cell Like Cells. Cancer management and research 11 (2019)

Yang Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yang Li